Abstract
The article tells about the experience with rivaroxaban for the prevention of stroke and thromboembolism not involving the central nervous system vessels in patients with non-valvular atrial fibrillation in a number of clinical cases. The article demonstrates that rivaroxaban’s efficacy and safety in everyday medical practice, in general, meets the expectations resulting from the large controlled ROCKET-AF trial.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
